Pharmaceutical

Opko and Entera focus on oral care for obesity and metabolic disorders

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of oral dual agonist GLP-1.

Mar 19, 2025 - 06:00
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of oral dual agonist GLP-1.
Read the original article

Tags:

Previous Article

Arbor to advance gene editing treatments with $73.9m funding

Next Article

Curevo procures $110m and former-GSK exec for shingles vaccine candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

HPV vaccines are so effective that new screening policies may be in order, suggests study

HPV vaccines are so effective that new screening polici...

Nov 9, 2023

STAT+: Key House Republican escalates rhetoric against PBMs

STAT+: Key House Republican escalates rhetoric against ...

Jun 14, 2023

FDA grants GSK first-ever approval for RSV vaccine

FDA grants GSK first-ever approval for RSV vaccine

May 4, 2023